Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Key Stats

• Today's Range: $8.73 to $9.03
• 50-Day Range: $8.60 to $9.79
• 52-Week Range: $7.11 to $10.04
• Volume: 2,386 shs
• Average Volume: 7,457 shs
• Market Capitalization: $43.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.75
• Consensus Rating: Buy

Daxor Stock Analysis - MarketRank™

Daxor scored higher than 82% of companies evaluated by MarketBeat, and ranked 221st out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Daxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Daxor has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.60% of the float of Daxor has been sold short.

Short Interest Ratio / Days to Cover

Daxor has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daxor has recently decreased by 3.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Daxor does not currently pay a dividend.

Dividend Growth

Daxor does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.60% of the float of Daxor has been sold short.

Short Interest Ratio / Days to Cover

Daxor has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daxor has recently decreased by 3.08%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Daxor has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Daxor this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daxor insiders have not sold or bought any company stock.

Percentage Held by Insiders

59.00% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.34% of the stock of Daxor is held by institutions.

DXR Stock Analysis - Frequently Asked Questions

How have DXR shares performed this year?

Daxor's stock was trading at $9.60 at the start of the year. Since then, DXR stock has decreased by 6.1% and is now trading at $9.01.
View the best growth stocks for 2024 here.

Who are Daxor's major shareholders?

Top institutional shareholders of Daxor include Keyes Stange & Wooten Wealth Management LLC (0.30%). Insiders that own company stock include Michael Richard Feldschuh and Robert J Michel.
View institutional ownership trends.

How do I buy shares of Daxor?

Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and

Company Calendar

• Today: 11/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DXR
• CUSIP: N/A
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.75
• High Stock Price Target: $24.75
• Low Stock Price Target: $24.75
• Potential Upside/Downside: +174.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,840,000
• Free Float: 1,983,000
• Market Cap: $43.61 million
• Optionable: Not Optionable
• Beta: -0.54